Royce & Associates LP Has $5.73 Million Holdings in Haemonetics Corporation $HAE

Royce & Associates LP lessened its stake in Haemonetics Corporation (NYSE:HAE – Free Report) by 89.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,475 shares of the medical instruments supplier’s stock after selling 629,767 shares during the quarter. Royce & Associates LP owned approximately 0.15% of Haemonetics worth $5,729,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Hantz Financial Services Inc. boosted its holdings in shares of Haemonetics by 52.5% in the 4th quarter. Hantz Financial Services Inc. now owns 1,714 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 590 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Haemonetics by 366.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,709 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 1,343 shares during the last quarter. Legato Capital Management LLC acquired a new stake in shares of Haemonetics in the 4th quarter valued at approximately $1,057,000. Global Retirement Partners LLC acquired a new stake in shares of Haemonetics in the 4th quarter valued at approximately $270,000. Finally, Leonteq Securities AG acquired a new stake in shares of Haemonetics in the 4th quarter valued at approximately $30,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Get Haemonetics alerts:

Haemonetics Stock Up 1.5%

HAE stock opened at $68.02 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of 33.67, a PEG ratio of 1.35 and a beta of 0.53. The business’s fifty day moving average price is $58.95 and its two-hundred day moving average price is $67.42. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32.

Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, equities analysts anticipate that Haemonetics Corporation will post 5.23 earnings per share for the current year.

Wall Street Analyst Weigh In

HAE has been the topic of a number of research analyst reports. Citigroup increased their price target on Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a research note on Thursday. Robert W. Baird set a $67.00 price target on Haemonetics in a research note on Friday, May 8th. JPMorgan Chase & Co. dropped their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Finally, Barrington Research dropped their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $77.11.

Get Our Latest Analysis on Haemonetics

Haemonetics Company Profile

(Free Report)

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

See Also

• Five stocks we like better than Haemonetics
• Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
• Salesforce Stock Finds Support as AI Momentum Builds
• Dollar Tree Keeps Winning After Family Dollar Divorce
• Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.